先健科技(01302.HK):IBS®可吸收藥物洗脱冠脈支架系統中國確證性臨牀首例成功入組
格隆匯3月14日丨先健科技(01302.HK)發佈公吿,2022年3月10日,集團自主研發的 IBS®可吸收藥物洗脱冠脈支架系統在雲南省阜外心血管病醫院順利完成中國確證性臨牀研究首例受試者入組。
根據披露, IBS®冠脈支架是全球首款全降解鐵基可吸收冠脈支架。其基體由高強度和高塑性的高純滲氮鐵管加工而成,支架壁薄且支撐力強。創新的材料研究和獨特的技術路徑,使本產品既保留了永久金屬冠脈支架規格齊全、物理性能優越、生物相容性好、操作簡單等優點,亦兼具完全可吸收的特性。 IBS®冠脈支架在完成對血管的有效支撐後(即植入後3-6個月)便開始降解,於2年左右安全進入降解尾聲,最終被人體組織所無害吸收,從而能夠有效避免植入永久支架可能帶來的一系列遠期預後問題。
IBS®冠脈支架中國確證性臨牀研究首例患者成功入組,是公司在鐵基生物可吸收材料研發歷程中的重大里程碑。隨着後續臨牀試驗的穩步推進,將會有更多的循證醫學證據進一步證實該產品的安全性和有效性,並將在產品成功上市後,為國內冠心病患者帶來前所未有的治療方式,同時為其進入全球市場奠定堅實基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.